BMO Capital has lowered the Target Price and rating for Bojian.
Leerink Partners Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $290
BMO Capital Downgrades Biogen(BIIB.US) to Hold Rating, Cuts Target Price to $164
Biogen's Challenges and Cautious Outlook: Hold Rating Amid Revenue Growth Struggles and Neurology Market Hurdles
Biogen Cut to Market Perform From Outperform by BMO Capital
Biogen Analyst Ratings
BMO Capital Downgrades Biogen to Market Perform, Lowers Price Target to $164
Stifel Downgrades Biogen(BIIB.US) to Hold Rating, Cuts Target Price to $175
Stifel Downgrades Biogen to Hold From Buy, Adjusts Price Target to $175 From $275
Biogen Analyst Ratings
B of A Securities Reinstates Neutral on Biogen, Announces $178 Price Target
Biogen Analyst Ratings
Jefferies Downgrades Biogen(BIIB.US) to Hold Rating, Cuts Target Price to $180
Biogen's Modest Growth Prospects and Revenue Challenges Highlighted in Hold Rating
Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS), Biogen (BIIB) and Edwards Lifesciences (EW)
Morgan Stanley Maintains Biogen(BIIB.US) With Hold Rating, Cuts Target Price to $192
RBC Capital Sticks to Its Buy Rating for Biogen (BIIB)
Jefferies Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $250
Jefferies Remains a Buy on Biogen (BIIB)
Biogen Is Maintained at Outperform by Mizuho